The urea cycle enzymes act as metabolic suppressors in clear cell renal cell carcinoma

Lucarelli, Giuseppe; Ferro, Matteo; Ditonno, Pasquale; Battaglia, Michele

doi:10.21037/tcr.2018.08.07

Cited by 10 publications

(6 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recent research has established that RCC is essentially a metabolic disease, even though the pathophysiology of the disease is still not entirely understood. Numerous studies have demonstrated that changes in metabolic pathways have a part in the development of RCC and that a significant amount of altered genes in this disease are essential for regulating the metabolic activities of cells [ 116 , 117 ].…”

Section: Muc1 Expression In Kidney Cancermentioning

confidence: 99%

The Role of MUC1 in Renal Cell Carcinoma

Milella,

Rutigliano,

Lasorsa

et al. 2024

Biomolecules

Self Cite

View full text Add to dashboard Cite

Mucins are a family of high-molecular-weight glycoproteins. MUC1 is widely studied for its role in distinct types of cancers. In many human epithelial malignancies, MUC1 is frequently overexpressed, and its intracellular activities are crucial for cell biology. MUC1 overexpression can enhance cancer cell proliferation by modulating cell metabolism. When epithelial cells lose their tight connections, due to the loss of polarity, the mucins become dispersed on both sides of the epithelial membrane, leading to an abnormal mucin interactome with the membrane. Tumor-related MUC1 exhibits certain features, such as loss of apical localization and aberrant glycosylation that might cause the formation of tumor-related antigen epitopes. Renal cell carcinoma (RCC) accounts for approximately 3% of adult malignancies and it is the most common kidney cancer. The exact role of MUC1 in this tumor is unknown. Evidence suggests that it may play a role in several oncogenic pathways, including proliferation, metabolic reprogramming, chemoresistance, and angiogenesis. The purpose of this review is to explore the role of MUC1 and the meaning of its overexpression in epithelial tumors and in particular in RCC.

show abstract

Section: Muc1 Expression In Kidney Cancermentioning

confidence: 99%

The Role of MUC1 in Renal Cell Carcinoma

Milella,

Rutigliano,

Lasorsa

et al. 2024

Biomolecules

Self Cite

View full text Add to dashboard Cite

show abstract

“…The 5-year survival rate in patients with advanced RCC is extremely low, ranging from 5-10%, because of recurrence and distant metastasis (2). Over the past decades, although medical treatment for RCC has great progress which transitioned from a surgical resection approach, to targeted therapy incorporates both surgical and systemic therapies, and now combining novel immunotherapy agents (3). However, despite these recent advances, RCC patients can still expect a dire prognosis A study reported that nearly 30% of all survivors of…”

Section: Introductionmentioning

confidence: 99%

The impact of insurance status on the survival outcomes of patients with renal cell carcinoma

Yan¹,

Zhu²,

Zhang³

2020

Transl Androl Urol

View full text Add to dashboard Cite

Background:The impact of insurance status on renal cell carcinoma (RCC) patient survival is unclear. In this study, we investigated the effects of insurance status on the survival outcomes of RCC patients in the United States of America.Methods: Data of patients diagnosed with RCC between 2007 and 2014 were obtained from the Surveillance, Epidemiology and End Results (SEER) database, a large national database including statistics on cancer patients. The Kaplan-Meier method and Cox regression analysis were used to determine the influence of insurance status on cancer-specific survival (CSS).Results: A total of 30,951 eligible RCC patients were identified. Of these patients, 25,493 (82.37%) were insured, 3,959 (12.79%) had any Medicaid coverage, and 1,499 (4.84%) were uninsured. Kaplan-Meier analysis revealed that insurance status was associated with better CCS (P<0.001). The 5-year CSS rates of patients with insurance, any Medicaid, and no insurance were 88.3%, 82.6%, and 82.7%, respectively.Multivariate Cox regression analysis showed that patients with any Medicaid had poorer CSS than insured patients [hazard ratio (HR), 1.222; 95% confidence interval (CI), 1.100-1.357]. Stratified analysis revealed that at localized tumor stage and at regional tumor stage or among white patients, any Medicaid insurance was an independent predictor of an unfavorable survival outcome.Conclusions: Among the RCC patients in this study, individuals with insurance experienced improved CSS while individuals with any Medicaid tended to suffer worse survival outcomes.

show abstract

“…Recent studies have suggested that RCC can be considered a metabolic disease, as changes in metabolism contribute to the development and progression of this cancer [ 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 , 10 ]. One of the main metabolic alterations in RCC is the activation of the hypoxia-inducible factor (HIF) pathway.…”

Section: Introductionmentioning

confidence: 99%

Immune Checkpoint Inhibitors in Renal Cell Carcinoma: Molecular Basis and Rationale for Their Use in Clinical Practice

et al. 2023

Self Cite

View full text Add to dashboard Cite

Renal cell carcinoma (RCC) is the seventh most common cancer in men and the ninth most common cancer in women worldwide. There is plenty of evidence about the role of the immune system in surveillance against tumors. Thanks to a better understanding of immunosurveillance mechanisms, immunotherapy has been introduced as a promising cancer treatment in recent years. Renal cell carcinoma (RCC) has long been thought chemoresistant but highly immunogenic. Considering that up to 30% of the patients present metastatic disease at diagnosis, and around 20–30% of patients undergoing surgery will suffer recurrence, we need to identify novel therapeutic targets. The introduction of immune checkpoint inhibitors (ICIs) in the clinical management of RCC has revolutionized the therapeutic approach against this tumor. Several clinical trials have shown that therapy with ICIs in combination or ICIs and the tyrosine kinase inhibitor has a very good response rate. In this review article we summarize the mechanisms of immunity modulation and immune checkpoints in RCC and discuss the potential therapeutic strategies in renal cancer treatment.

show abstract

The urea cycle enzymes act as metabolic suppressors in clear cell renal cell carcinoma

Cited by 10 publications

References 25 publications

The Role of MUC1 in Renal Cell Carcinoma

The Role of MUC1 in Renal Cell Carcinoma

The impact of insurance status on the survival outcomes of patients with renal cell carcinoma

Immune Checkpoint Inhibitors in Renal Cell Carcinoma: Molecular Basis and Rationale for Their Use in Clinical Practice

Contact Info

Product

Resources

About